Precision BioSciences (Precision BioSciences (DTIL)) is having a good Wednesday. The stock jumped 10.55% in premarket trading after the company released new clinical data from its PBGENE-HBV program, which is aimed at treating chronic hepatitis B. The data showed that the therapy effectively eliminates cccDNA — the persistent form of the virus that makes chronic hepatitis B so hard to cure — leading to a 10-fold reduction in cccDNA-derived transcripts. Even more striking, 100% of patients who had detectable pgRNA at baseline achieved pgRNA loss. That's the kind of result that gets investors excited.
Over the past 12 months, the stock has gained 55.01%, and the current price of $8.38 reflects strong momentum. The stock is trading 12.2% above its 20-day simple moving average of $7.45, 19.4% above its 50-day SMA of $7.00, and well above its 100-day and 200-day SMAs of $5.59 and $5.49. The 20-day exponential moving average is at $7.36, and the 50-day EMA is at $6.86, both supporting the bullish trend. The Relative Strength Index sits at 54.88, which is neutral — not overbought, not oversold — suggesting there's room to run.
On the technical side, keep an eye on two levels: key resistance at $8.82, the 52-week high, and key support at $7.45, which aligns with the 20-day SMA. If the current momentum continues, the stock could test that resistance level.
Looking ahead, the next major catalyst is the earnings report, expected around August 6, 2026. Analysts estimate a loss of 58 cents per share, a significant improvement from the prior loss of $2.13. Revenue is expected to come in at $2.06 million, up from just $18,000. That's a big jump, reflecting the company's progress.
Analysts are bullish. The stock carries a Buy rating with an average price target of $30.00. Jones Trading recently reiterated a Buy with a $30 target on April 17. That's a lot of upside from the current $8.38.
MarketDash's momentum score for Precision BioSciences is 92.66, which is strongly bullish. The stock is outperforming the broader market, and the signal suggests a strong momentum-driven story. Investors should keep an eye on upcoming developments as the company advances its therapies.
As of Wednesday premarket, DTIL shares were up 10.55% at $8.38.
